This data supports claims raised in a growing number of lawsuits filed against manufacturers, including Novo Nordisk and Eli Lilly
These therapies are increasingly recognized for their benefits in managing cardiovascular, renal, and metabolic conditions, which are common comorbidities among patients with T2D
By addressing insulin resistance, hormonal imbalances, and related symptoms simultaneously, Oana Health offers a more comprehensive solution
Without them, you cannot tell whether the supplement caused the results or whether the same results would have occurred from dietary guidance and accountability alone
Conclusion The story of GLP-1 medications is rapidly evolving
Sources: FDA drug shortage announcements for tirzepatide (October 2024) and semaglutide (February 2025)